0001104659-26-059023
SEC filingRevenue accelerated 19.6% to $14.8M amid U.S. commercialization while gross margins expanded to 87.2% from manufacturing efficiencies and higher average selling prices, narrowing operating and net losses as investments continue.
Revenue increased 19.6% to $14.8 million in Q1 FY2026 from $12.3 million prior year, signaling sustained U.S. commercialization traction for Barostim despite heavy investments. This growth underscores execution in a growth-stage medtech profile, where scaling sales aligns with management's focus on market expansion.
Gross profit rose 24.9% to $12.9 million, yielding a 87.2% gross margin—higher than the prior period's implied rate—due to an increase in average selling price and lower cost per unit from manufacturing efficiencies. As noted in MD&A, manufacturing overhead for Barostim ties directly to production volume, reducing per-product costs as output rises to meet demand. This dynamic protects against supply interruptions via elevated inventory levels and diversified sourcing, while supporting operational growth through net operating assets like inventory and receivables.
Management emphasizes ongoing net losses for years ahead due to commercialization investments, potentially requiring equity or debt raises. Future liquidity hinges on U.S. investment scale, supply chain resilience, and Barostim production ramps. Cost of goods sold—spanning components, overhead, scrap, obsolescence, and logistics—remains volume-sensitive, positioning margins for further leverage if demand sustains. This quarter's metrics affirm a path toward profitability through efficiency gains and revenue scale, though execution amid payer, supply, and competitive risks persists.